Cognition Therapeutics Inc (CGTX) Stock Price, Quote & News

Company Profile

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as ge...

Industry: Biotechnology

Sector: Healthcare

Phone: 412 481 2210

Website: www.cogrx.com

Address:

2500 Westchester Ave., Purchase, United States

MITCH1099 Apr. 4 at 7:40 PM

$CGTX Up 46% since my post. 😀

0 · Reply

Duskfall Apr. 4 at 6:15 PM

Happy Easter everyone! I hope you took advantage of the dip. Starting next week, this will be working 💯 $VXRT $BTAI $AEMD $TOVX $CGTX

0 · Reply

makingdoughfromoptions Apr. 3 at 4:20 PM

$CGTX I added about 5,000 shares Thurs and yesterday and will add another 5,000 next week. I made some good coin many months ago and think their Lewy program will eventually be approved and possibly their ALZ subset market. Expect dilution but right now a deal even with probably dilution.

0 · Reply

SharkLips Apr. 2 at 8:30 PM

$CGTX next week, oh my....Haramizawa!

0 · Reply

Brutusmabel Apr. 2 at 8:01 PM

$CGTX like what I saw going into closing, strong finish, volume picked up. Could be an after hrs gains situation

0 · Reply

Brutusmabel Apr. 2 at 7:34 PM

$CGTX it’s a short attack, short shares available was at 1.7 last few days and now within the last hr it’s 1.3 available. Short attack!!

0 · Reply

Brutusmabel Apr. 2 at 7:28 PM

$CGTX man I hate kick in the nuts, idk that’s weird, maybe shaking out weak jambs and we could see a rebound?? Weird we get 200,000 shares traded in a half hr and 600 in 6 hrs

0 · Reply

Marshallmathers1 Apr. 2 at 7:27 PM

$CGTX lol.

0 · Reply

Brutusmabel Apr. 2 at 7:21 PM

$CGTX looking at the stock closely I still firmly believe entry point under a dollar is fantastic for this so hopefully people catch on and open a position and get this thing moving

0 · Reply

Brutusmabel Apr. 2 at 7:20 PM

$CGTX $RENX hopefully some of you guys got in 👍🤞

0 · Reply

Cognition Therapeutics CEO Issues Letter to Shareholders

Mar 26, 2026, 7:30 AM EDT - 10 days ago

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

Mar 23, 2026, 7:30 AM EDT - 13 days ago

Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results

Mar 17, 2026, 7:30 AM EDT - 19 days ago

Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026

Mar 2, 2026, 7:30 AM EST - 4 weeks ago

Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis

Feb 5, 2026, 7:30 AM EST - 2 months ago

Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

Jan 27, 2026, 7:30 AM EST - 2 months ago

Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies

Jan 6, 2026, 7:30 AM EST - 3 months ago

Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies

Dec 1, 2025, 7:30 AM EST - 4 months ago

Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference

Nov 20, 2025, 4:01 PM EST - 4 months ago

Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference

Nov 13, 2025, 7:36 AM EST - 5 months ago

Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer's Disease

Nov 6, 2025, 7:30 AM EST - 5 months ago

Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs

Sep 3, 2025, 7:30 AM EDT - 7 months ago

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment Target

Sep 2, 2025, 4:00 PM EDT - 7 months ago

Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)

Aug 27, 2025, 8:53 PM EDT - 7 months ago

Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock

Aug 26, 2025, 4:00 PM EDT - 7 months ago

Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aug 12, 2025, 4:00 PM EDT - 8 months ago

Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's Disease

Jul 29, 2025, 7:30 AM EDT - 8 months ago

Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease

Jul 21, 2025, 7:30 AM EDT - 9 months ago

Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's Disease

Jul 16, 2025, 7:30 AM EDT - 9 months ago

Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC

Jul 10, 2025, 7:30 AM EDT - 9 months ago

Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's Disease

Jul 1, 2025, 7:30 AM EDT - 9 months ago

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Surpasses 50% Enrollment Target

Jun 25, 2025, 7:30 AM EDT - 10 months ago

Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer's Disease and Dementia with Lewy Bodies (DLB)

Jun 3, 2025, 7:30 AM EDT - 10 months ago

Philanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

May 28, 2025, 7:30 AM EDT - 11 months ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies

May 9, 2025, 7:30 AM EDT - 11 months ago

Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health

May 7, 2025, 7:30 AM EDT - 11 months ago

Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update

Apr 1, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025

Mar 20, 2025, 7:00 AM EDT - 1 year ago

Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update

Mar 13, 2025, 4:05 PM EDT - 1 year ago

Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results

Mar 12, 2025, 4:05 PM EDT - 1 year ago

Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing

Mar 10, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference

Feb 27, 2025, 7:30 AM EST - 1 year ago

Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD

Feb 25, 2025, 7:30 AM EST - 1 year ago

Cognition Therapeutics' VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit

Jan 30, 2025, 7:30 AM EST - 1 year ago

Cognition's Positive Phase 2 ‘SHIMMER' Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC

Jan 8, 2025, 4:14 PM EST - 1 year ago

Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences

Dec 18, 2024, 11:06 AM EST - 1 year ago

Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday?

Dec 18, 2024, 7:22 AM EST - 1 year ago

Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

Nov 26, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies

Nov 25, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics' Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer's Population

Nov 13, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

Nov 12, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

Oct 31, 2024, 4:15 PM EDT - 1 year ago

Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

Oct 29, 2024, 12:55 PM EDT - 1 year ago

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Analyses from Cognition's Positive Phase 2 ‘SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTAD

Oct 22, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

Oct 2, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference

Oct 1, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

MITCH1099 Apr. 4 at 7:40 PM

$CGTX Up 46% since my post. 😀

0 · Reply

Duskfall Apr. 4 at 6:15 PM

Happy Easter everyone! I hope you took advantage of the dip. Starting next week, this will be working 💯 $VXRT $BTAI $AEMD $TOVX $CGTX

0 · Reply

makingdoughfromoptions Apr. 3 at 4:20 PM

0 · Reply

SharkLips Apr. 2 at 8:30 PM

$CGTX next week, oh my....Haramizawa!

0 · Reply

Brutusmabel Apr. 2 at 8:01 PM

$CGTX like what I saw going into closing, strong finish, volume picked up. Could be an after hrs gains situation

0 · Reply

Brutusmabel Apr. 2 at 7:34 PM

$CGTX it’s a short attack, short shares available was at 1.7 last few days and now within the last hr it’s 1.3 available. Short attack!!

0 · Reply

Brutusmabel Apr. 2 at 7:28 PM

$CGTX man I hate kick in the nuts, idk that’s weird, maybe shaking out weak jambs and we could see a rebound?? Weird we get 200,000 shares traded in a half hr and 600 in 6 hrs

0 · Reply

Marshallmathers1 Apr. 2 at 7:27 PM

$CGTX lol.

0 · Reply

Brutusmabel Apr. 2 at 7:21 PM

$CGTX looking at the stock closely I still firmly believe entry point under a dollar is fantastic for this so hopefully people catch on and open a position and get this thing moving

0 · Reply

Brutusmabel Apr. 2 at 7:20 PM

$CGTX $RENX hopefully some of you guys got in 👍🤞

0 · Reply

goldenxb Apr. 2 at 7:17 PM

$CGTX up to 10,500 shares now; nothing about our fundamentals have changed…except a damn short attack

0 · Reply

Brutusmabel Apr. 2 at 7:13 PM

$CGTX here comes a short attack, they’re trying to hold us down even though it’s got very low volume. Add if you can I’m gonna add 430 shares not much but it’s the most I can do for the rest of today I’ve been adding all day at 83.

0 · Reply

TwizzlersForSale Apr. 2 at 6:57 PM

$CGTX I guess I’m really confused by the recent action here & constant excitement of “we’ll be over a 1$ soon” posts when..we dropped from 1 to about -50% in a day or two… you’re excited to be back less than where we started? 🤔

1 · Reply

Brutusmabel Apr. 2 at 6:51 PM

$CGTX the other thing that is killing us is whatever buying power we do have nobody is hitting the ass, so kind of fighting against ourselves

0 · Reply

Brutusmabel Apr. 2 at 6:42 PM

$CGTX this really wants to go haha, man if the volume was twice what it is we’d be $1

0 · Reply

nostic Apr. 2 at 6:28 PM

$CGTX so crazy... this stock was so quiet and stable for a long time, then in the past week, all over the place. The bid/ask liquidity is just gone. Even when the bid/ask looked very thin, I could buy or sell 10-20k shares at the bid or ask. Wonder what is going on. What do you all think is the reason for the sudden volatility? Iran-US war? Institutional selling/buying? Day-traders?

4 · Reply

Brutusmabel Apr. 2 at 6:11 PM

$CGTX $RENX it might be starting to pop off now!! 🤑🤑🤞

1 · Reply

Brutusmabel Apr. 2 at 6:07 PM

$RENX my friends here, come over to $CGTX, it’s set up to make a move, it’s needs volume but this is another great short play right now. Make some money there while you’re his is stalling

0 · Reply

Brutusmabel Apr. 2 at 5:30 PM

$CGTX paitencemighg pay off here, shorts trying to f us by placing bids lower than price but short attack coming possible

0 · Reply

Brutusmabel Apr. 2 at 4:38 PM

$CGTX

0 · Reply

Marshallmathers1 Apr. 2 at 4:29 PM

$CGTX Definitely needed a good heathy cool off day.

1 · Reply

stockthoughts9282 Apr. 2 at 4:05 PM

$CGTX Bought two shares. Asked AI for a cheap stock. Lol.

1 · Reply

Market Cap	77.56M
Revenue (ttm)	0.00
Net Income (ttm)	-23.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,048,900
Avg Vol	1,094,572
Day's Range	N/A - N/A
Shares Out	89.35M
Stochastic %K	49%
Beta	1.39
Analysts	Strong Sell
Price Target	$3.50